Variant report
Variant | esv3523797 |
---|---|
Chromosome Location | chr8:11244392-11248290 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:13)
- CpG islands (count:0)
- Chromatin interactive region (count:2)
- LncRNA region (count:1)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
(count:13 , 50 per page) page:
1
No. | Transcrition factor | Chromosome Location | Cell Line | Cell type | Cell Stage | Matched TF binding sites |
---|---|---|---|---|---|---|
1 | CTCF | chr8:11247820-11247970 | GM12865 | blood: | n/a | n/a |
2 | CTCF | chr8:11247880-11248030 | GM12872 | blood: | n/a | n/a |
3 | CTCF | chr8:11247889-11247918 | H1-hESC | embryonic stem cell: | n/a | n/a |
4 | CTCF | chr8:11247860-11248010 | GM12873 | blood: | n/a | n/a |
5 | CTCF | chr8:11247780-11247930 | HepG2 | liver: | n/a | n/a |
6 | CTCF | chr8:11245280-11245430 | GM06990 | blood: | n/a | n/a |
7 | GATA3 | chr8:11244654-11245125 | MCF-7 | breast: | n/a | n/a |
8 | MAFF | chr8:11246513-11246670 | HepG2 | liver: | n/a | chr8:11246597-11246611 chr8:11246598-11246616 |
9 | MAFK | chr8:11246439-11246723 | HepG2 | liver: | n/a | chr8:11246597-11246611 chr8:11246594-11246614 chr8:11246596-11246612 chr8:11246599-11246614 |
10 | MAFK | chr8:11246526-11246726 | HepG2 | liver: | n/a | chr8:11246597-11246611 chr8:11246594-11246614 chr8:11246596-11246612 chr8:11246599-11246614 |
11 | MYC | chr8:11245996-11246142 | H1-hESC | embryonic stem cell: | n/a | n/a |
12 | POLR2A | chr8:11247328-11247426 | Gliobla | brain: | n/a | n/a |
13 | POLR2A | chr8:11247773-11247777 | Gliobla | brain: | n/a | n/a |
No data |
(count:2 , 50 per page) page:
1
(count:1 , 50 per page) page:
1
No. | lncRNA name | Chromosome Location | lncRNA alias |
---|---|---|---|
1 | lnc-C8orf12-1 | chr8:11247933-11248244 | NONHSAT125054 |
No data |
No data |
Variant related genes | Relation type |
---|---|
C8orf12 | TF binding region |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs537282887 | chr8:11244619-11244620 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs552071192 | chr8:11244636-11244637 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs368767116 | chr8:11244668-11244669 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
4 | rs181399530 | chr8:11244686-11244687 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
5 | rs534636254 | chr8:11244706-11244707 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
6 | rs111290307 | chr8:11244716-11244717 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
7 | rs143886095 | chr8:11244717-11244718 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
8 | rs535451857 | chr8:11244773-11244774 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
9 | rs60625333 | chr8:11244793-11244794 | Enhancers | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
10 | rs549607177 | chr8:11244815-11244816 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
11 | rs564089832 | chr8:11244819-11244820 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
12 | rs115284871 | chr8:11244832-11244833 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
13 | rs6980481 | chr8:11244841-11244842 | Enhancers | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
14 | rs28432983 | chr8:11244857-11244858 | Enhancers | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
15 | rs551885687 | chr8:11244870-11244871 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
16 | rs148634645 | chr8:11244871-11244872 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
17 | rs75910389 | chr8:11244874-11244875 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
18 | rs34867058 | chr8:11244887-11244888 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
19 | rs562321201 | chr8:11244909-11244910 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
20 | rs529762511 | chr8:11244935-11244936 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
21 | rs548201021 | chr8:11244951-11244952 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
22 | rs185485348 | chr8:11244953-11244954 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
23 | rs530600083 | chr8:11244960-11244961 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
24 | rs552223570 | chr8:11244984-11244985 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
25 | rs190093809 | chr8:11244989-11244990 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
26 | rs534777395 | chr8:11244990-11244991 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
27 | rs142135935 | chr8:11245017-11245018 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
28 | rs527731083 | chr8:11245025-11245026 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
29 | rs535489984 | chr8:11245036-11245037 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
30 | rs181063383 | chr8:11245053-11245054 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
31 | rs1560971 | chr8:11245064-11245065 | Enhancers | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
32 | rs185902800 | chr8:11245091-11245092 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
33 | rs192422954 | chr8:11245097-11245098 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
34 | rs573359249 | chr8:11245217-11245218 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs540818907 | chr8:11245232-11245233 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs79177516 | chr8:11245261-11245262 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs183978544 | chr8:11245268-11245269 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs574372516 | chr8:11245271-11245272 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs554000135 | chr8:11245276-11245277 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs374031260 | chr8:11245279-11245280 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs12682349 | chr8:11245303-11245304 | Weak transcription Enhancers | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
42 | rs563296797 | chr8:11245325-11245326 | Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
43 | rs549026086 | chr8:11245342-11245343 | Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
44 | rs545592000 | chr8:11245350-11245351 | Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
45 | rs564163116 | chr8:11245382-11245383 | Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
46 | rs528313590 | chr8:11245423-11245424 | Weak transcription Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
47 | rs187745005 | chr8:11245453-11245454 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs568041104 | chr8:11245485-11245486 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs151195312 | chr8:11245489-11245490 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs536415570 | chr8:11245493-11245494 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Crohn''s disease | 19220326 | CNVD |
Psoriasis | 19220326 | CNVD |
Prostate cancer | 21965145 | CNVD |
Prostate cancer | 18515986 | CNVD |
Chronic obstructive pulmonary disease | 20378733 | CNVD |
Autism | 18414403 | CNVD |
Cancer | 21183584 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Breast cancer | 17603634 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Ovarian cancer | 20844748 | CNVD |
Cervical cancer | 17311676 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
Non-syndromic sensorineural hearing loss | 20606397 | CNVD |
Schizophrenia | 20877625 | CNVD |
Disorders of sex development | 21048976 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Basal cell lymphoma | 17170743 | CNVD |
Follicular lymphoma | 17170743 | CNVD |
Breast cancer | 17001317 | CNVD |
Thyroid cancer | 19087340 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Heart disease | 21282601 | CNVD |
Prostate cancer | 16573809 | CNVD |
T-cell lymphomas | 19863542 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Colorectal cancer | 21297112 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Salivary gland tumor | 18059337 | CNVD |
Breast cancer | 17133270 | CNVD |
Melanoma | 18172304 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Chronic lymphocytic leukemia | 18922857 | CNVD |
Breast cancer | 17393978 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Cancer | 21637783 | CNVD |
Breast cancer | 20837533 | CNVD |
Squamous cell cancer | 21044232 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Cancer | 22429812 | CNVD |
Non-small cell lung cancer | 21044232 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Basal cell lymphoma | 21115979 | CNVD |
Breast cancer | 21264507 | CNVD |
Carcinoma ex pleomorphic adenoma | 18828159 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Oral cancer | 21386901 | CNVD |
Prostate cancer | 21088497 | CNVD |
Breast cancer | 20940404 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Gastric cancer | 17167181 | CNVD |
Prostate cancer | 16705090 | CNVD |
8p-syndrome | 17576883 | CNVD |
Human rectal carcinomas | 16397240 | CNVD |
Medulloblastoma | 16968546 | CNVD |
Lung adenocarcinoma | 19525976 | CNVD |
Lung cancer | 19525976 | CNVD |
Prostate cancer | 17245344 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Cancer | 16751803 | CNVD |
Wilms tumour | 21544195 | CNVD |
Gastric cancer | 17908304 | CNVD |
Autism | 19415332 | CNVD |
Malaria | 21533027 | CNVD |
Non-syndromic sensorineural hearing loss | 22037309 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Acute promyelocytic leukemia | 19109227 | CNVD |
Breast cancer | 21245420 | CNVD |
Acute lymphoblastic leukemia | 21248843 | CNVD |
Breast cancer | 21785460 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
Breast cancer | 21509527 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Prostate cancer | 18632612 | CNVD |
Breast cancer | 21858162 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Liver carcinoma | 19366792 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Congenital diaphragmatic hernia | 21064195 | CNVD |
Autism | 22495311 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Intellectual disability | 22045946 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Breast cancer | 16608533 | CNVD |
Seminomas | 18059402 | CNVD |
Lung cancer | 18438408 | CNVD |
Lung squamous cell carcinoma | 22363434 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Gastric cancer | 18160780 | CNVD |
Breast cancer | 21990379 | CNVD |
Psoriasis | 20403174 | CNVD |
Psoriasis | 20663923 | CNVD |
Crohn''s disease | 16909382 | CNVD |
Cancer | 21129771 | CNVD |
Congenital diaphragmatic hernia | 21085971 | CNVD |
Crohn''s disease | 20877625 | CNVD |
Inflammatory disorder | 20877625 | CNVD |
Cardiac defect | 21933911 | CNVD |
Psoriasis | 18059266 | CNVD |
Barrett''s adenocarcinoma | 18663352 | CNVD |
Psoriasis | 20877625 | CNVD |
Mental retardation | 17847001 | CNVD |
Prostate cancer | 17217626 | CNVD |
Schizophrenia | 21399695 | CNVD |
Colorectal cancer | 21128281 | CNVD |
Colorectal cancer | 19455253 | CNVD |
Psoriasis | 18848619 | CNVD |
Squamous cell cancer | 19047905 | CNVD |
Colorectal cancer | 17229543 | CNVD |
Gastrointestinal stromal cancer | 19259404 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Myxofibrosarcoma | 16751306 | CNVD |
Immune disease | 21572526 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Ovarian neoplasms | 16753589 | CNVD |
Kallmann Syndrome 2 | 22470819 | CNVD |
Developmental disorder | 20461109 | CNVD |
abnormal development | 18461090 | CNVD |
Ovarian clear cell carcinoma | 21343371 | CNVD |
Glioblastoma multiforme | 21138945 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Breast cancer | 21364760 | CNVD |
Gastric cancer | 21811585 | CNVD |
Colorectal cancer | 16774939 | CNVD |
Acute lymphoblastic leukemia | 21390130 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Breast cancer | 22522925 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr8:11244600-11244800 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
2 | chr8:11244600-11248000 | Enhancers | Pancreas | Pancrea |
3 | chr8:11244800-11245000 | Enhancers | iPS DF 6.9 Cell Line | embryonic stem cell |
4 | chr8:11244800-11245200 | Enhancers | Breast variant Human Mammary Epithelial Cells (vHMEC) | Breast |
5 | chr8:11244800-11245600 | Enhancers | NHEK | skin |
6 | chr8:11245000-11245200 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
7 | chr8:11245200-11247800 | Weak transcription | ES-UCSF4 Cell Line | embryonic stem cell |
8 | chr8:11245600-11247200 | Weak transcription | NHEK | skin |
9 | chr8:11246200-11246600 | Bivalent Enhancer | Fetal Adrenal Gland | Adrenal Gland |
10 | chr8:11246400-11246600 | Enhancers | Gastric | stomach |
11 | chr8:11246600-11250200 | Weak transcription | Gastric | stomach |
12 | chr8:11247200-11247400 | Bivalent Enhancer | Foreskin Keratinocyte Primary Cells skin02 | Skin |
13 | chr8:11247200-11248200 | Bivalent Enhancer | NHEK | skin |
14 | chr8:11247400-11248200 | ZNF genes & repeats | iPS DF 19.11 Cell Line | embryonic stem cell |
15 | chr8:11247600-11247800 | Weak transcription | iPS DF 6.9 Cell Line | embryonic stem cell |
16 | chr8:11247800-11248000 | Enhancers | Spleen | Spleen |
17 | chr8:11247800-11248400 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
18 | chr8:11247800-11248600 | Enhancers | iPS DF 6.9 Cell Line | embryonic stem cell |
19 | chr8:11247800-11248600 | Enhancers | Foreskin Keratinocyte Primary Cells skin03 | Skin |
20 | chr8:11248000-11250200 | Weak transcription | Pancreas | Pancrea |
21 | chr8:11248200-11248400 | Bivalent Enhancer | H9 Derived Neuron Cultured Cells | ES cell derived |
22 | chr8:11248200-11248600 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |
23 | chr8:11248200-11248600 | Flanking Bivalent TSS/Enh | NHEK | skin |
24 | chr8:11248200-11249000 | Enhancers | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
25 | chr8:11248200-11249000 | Bivalent Enhancer | Foreskin Keratinocyte Primary Cells skin02 | Skin |